Medexus Pharmaceuticals Inc. — Capital/Financing Update 2021

Feb 17, 2021

==> picture [149 x 52] intentionally omitted <==

Borden Ladner Gervais LLP Bay Adelaide Centre, East Tower 22 Adelaide Street West Toronto, ON, Canada M5H 4E3 T 416.367.6000 F 416.367.6749 blg.com

==> picture [149 x 64] intentionally omitted <==

February 17, 2021

VIA SEDAR

British Columbia Securities Commission Alberta Securities Commission Ontario Securities Commission Financial and Consumer Affairs Authority of Saskatchewan The Manitoba Securities Commission Autorité des marchés financiers Financial and Consumer Services Commission (New Brunswick) Nova Scotia Securities Commission Office of the Superintendent of Securities (Prince Edward Island) Office of the Superintendent of Securities (Newfoundland and Labrador)

Dear Sirs/Mesdames,

Re: Medexus Pharmaceuticals Inc. (the “Company”) Short Form Prospectus dated February 17, 2021

We refer to the short form prospectus of the Company dated February 17, 2021 (the “ Prospectus ”), relating to the distribution of units.

We hereby consent to the references to our firm name on the third cover page of the Prospectus, under the heading “Plan of Distribution”, under the heading “Legal Matters” and under the heading “Interests of Experts”. We also consent to the reference to and use of our name and opinion under the heading “Eligibility for Investment”.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that are derived from our opinion referred to above or that are within our knowledge as a result of the services performed by us in connection with such opinion.

Yours truly,

(signed) “ Borden Ladner Gervais LLP ”

119129117:v1

Lawyers | Patents & Trade-mark Agents